WallStSmart

Elevance Health Inc (ELV)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 217% more annual revenue ($200.42B vs $63.32B). PFE leads profitability with a 11.8% profit margin vs 2.6%. ELV appears more attractively valued with a PEG of 1.47. ELV earns a higher WallStSmart Score of 56/100 (C).

ELV

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.66

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ELVUndervalued (+4.5%)

Margin of Safety

+4.5%

Fair Value

$416.35

Current Price

$415.53

$0.82 discount

UndervaluedFair: $416.35Overvalued
PFEUndervalued (+13.8%)

Margin of Safety

+13.8%

Fair Value

$30.21

Current Price

$26.04

$4.17 discount

UndervaluedFair: $30.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELV4 strengths · Avg: 8.3/10
Market CapQuality
$87.28B9/10

Large-cap with strong market position

P/E RatioValuation
17.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$4.10B8/10

Generating 4.1B in free cash flow

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$148.19B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

ELV3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Profit MarginProfitability
2.6%3/10

2.6% margin — thin

EPS GrowthGrowth
-16.8%2/10

Earnings declined 16.8%

PFE3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, EPS Growth. Thin 2.6% margins leave little buffer for downturns.

Bear Case : PFE

The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

ELV carries more volatility with a beta of 0.68 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

ELV generates stronger free cash flow (4.1B), providing more financial flexibility.

Monitor HEALTHCARE PLANS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ELV scores higher overall (56/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?